Skip to content

Clinical trials

Antiphospholipid Syndrome trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Antiphospholipid Syndrome Phase: Not applicable Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20051
20132
20184
20221
20231
20242
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Recruiting6
Unknown status3
Not yet recruiting2
Terminated2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Central Hospital, Nancy, France3
Centre Hospitalier Universitaire de Nīmes2
New Valley University2
Assiut University1
Bioray Laboratories1
CHU de Reims1
Centre Hospitalier Universitaire, Amiens1
China Immunotech (Beijing) Biotechnology Co., Ltd.1
Hospital Universitario Pedro Ernesto1
Institute of Hematology & Blood Diseases Hospital, China1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Antiphospholipid Syndrome21
Lupus Erythematosus, Systemic7
Scleroderma, Systemic5
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis4
Myositis4
Sjogren's Syndrome4
Thrombophilia2
Arthritis1
Communicable Diseases1
Connective Tissue Diseases1

Trials

Showing 51 to 21 of 21. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.